<p>Targeting Trop-2 in solid tumors: future prospects</p>
Saif Zaman(University of South Florida), Jhanelle E. Gray(Moffitt Cancer Center)
Cited by 158
Related Papers
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
|Clinical Cancer Research|2024|42
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
|International Journal of Radiation Oncology*Biology*Physics|2023|18